These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Pathological roles of α-synuclein in neurological disorders. Vekrellis K; Xilouri M; Emmanouilidou E; Rideout HJ; Stefanis L Lancet Neurol; 2011 Nov; 10(11):1015-25. PubMed ID: 22014436 [TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study. Jellinger KA Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452 [TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein pathology affecting Bergmann glia of the cerebellum in patients with alpha-synucleinopathies. Piao YS; Mori F; Hayashi S; Tanji K; Yoshimoto M; Kakita A; Wakabayashi K; Takahashi H Acta Neuropathol; 2003 Apr; 105(4):403-9. PubMed ID: 12624794 [TBL] [Abstract][Full Text] [Related]
10. Alpha-synuclein accumulates in Purkinje cells in Lewy body disease but not in multiple system atrophy. Mori F; Piao YS; Hayashi S; Fujiwara H; Hasegawa M; Yoshimoto M; Iwatsubo T; Takahashi H; Wakabayashi K J Neuropathol Exp Neurol; 2003 Aug; 62(8):812-9. PubMed ID: 14503637 [TBL] [Abstract][Full Text] [Related]
12. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Jellinger KA Biochim Biophys Acta; 2009 Jul; 1792(7):730-40. PubMed ID: 18718530 [TBL] [Abstract][Full Text] [Related]
13. [Role of genetics in the etiology of synucleinopathies]. Elcoroaristizabal Martín X; Gómez Busto F; González Fernández MC; de Pancorbo MM Rev Esp Geriatr Gerontol; 2011 Oct; 46 Suppl 1():3-11. PubMed ID: 22152908 [TBL] [Abstract][Full Text] [Related]
14. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Lee VM; Trojanowski JQ Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225 [TBL] [Abstract][Full Text] [Related]
16. Early alpha-synuclein lipoxidation in neocortex in Lewy body diseases. Dalfó E; Ferrer I Neurobiol Aging; 2008 Mar; 29(3):408-17. PubMed ID: 17166629 [TBL] [Abstract][Full Text] [Related]
17. Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Dev KK; Hofele K; Barbieri S; Buchman VL; van der Putten H Neuropharmacology; 2003 Jul; 45(1):14-44. PubMed ID: 12814657 [TBL] [Abstract][Full Text] [Related]
18. Aggregation of alpha-synuclein/NACP in the neuronal and glial cells in diffuse Lewy body disease: a survey of six patients. Piao YS; Wakabayashi K; Hayashi S; Yoshimoto M; Takahashi H Clin Neuropathol; 2000; 19(4):163-9. PubMed ID: 10919347 [TBL] [Abstract][Full Text] [Related]
19. ɑ-Synuclein strains and the variable pathologies of synucleinopathies. Peelaerts W; Baekelandt V J Neurochem; 2016 Oct; 139 Suppl 1():256-274. PubMed ID: 26924014 [TBL] [Abstract][Full Text] [Related]
20. Selective detection, quantification, and subcellular location of alpha-synuclein aggregates with a protein aggregate filtration assay. Kramer ML; Behrens C; Schulz-Schaeffer WJ Biotechniques; 2008 Mar; 44(3):403-11. PubMed ID: 18361794 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]